Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population

摘要

To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA). CCL27 in plasma samples from 104 NPC patients, 112 VCA-IgA–positive healthy donors, and 140 VCA-IgA–negative normal subjects was measured by ELISA. Expression of CCL27 in nasopharyngeal tissue from 20 VCA-IgA–positive healthy donors and 20 NPC patients was examined by immunohistochemical staining. Levels of CCL27 in the plasma of VCA-IgA–positive healthy donors (607.33?±?218.81?pg/ml) were significantly higher than the levels in all NPC patients (437.09?±?217.74, P?=?< 0.0001) and in the subset of patients with early stage NPC (463.85?±?226.17, P?=?0.0126). Plasma CCL27 levels were significantly lower in the VCA-IgA–negative normal subjects (358.22?±?133.15?pg/ml) than in either the VCA-IgA–positive healthy donors (P?